Combined weekly topotecan and biweekly bevacizumab in women with platinum-resistant ovarian, peritoneal, or fallopian tube cancer: Results of a Phase 2 Study

Kathryn F. McGonigle, Howard G. Muntz, Jacqueline Vuky, Pamela J. Paley, Dan S. Veljovich, Benjamin E. Greer, Barbara A. Goff, Heidi J. Gray, Thomas W. Malpass

Research output: Contribution to journalArticle

55 Scopus citations

Abstract

BACKGROUND: A phase 2 trial was conducted to determine the toxicity and efficacy of combined weekly topotecan and biweekly bevacizumab in patients with primary or secondary platinum-resistant ovarian, peritoneal, or fallopian tube cancer (OC). METHODS: Patients were treated with bevacizumab 10 mg/kg on days 1 and 15 and topotecan 4 mg/m2 on days 1, 8, and 15 of a 28-day cycle until progressive disease (PD) or excessive toxicity. The primary endpoint was progression-free survival (PFS); secondary objectives included overall survival (OS), objective response, and toxicity. RESULTS: Patients (N = 40) received a median of 8 treatment cycles. Toxicity was generally mild or moderate, with neutropenia (18%), hypertension (20%), gastrointestinal toxicity (18%), pain (13%), metabolic toxicity (15%), bowel obstruction (10%), and cardiotoxicity (8%) being the most common grade 3 and 4 adverse events. No bowel perforations, febrile neutropenia, or treatment-related deaths occurred. Median PFS and OS were 7.8 (95% confidence interval [CI], 3.0-9.4) and 16.6 months (95% CI, 12.8-22.9), with 22 (55%) patients progression-free for ≥6 months. Ten (25%) patients had partial response (PR), 14 (35%) had stable disease (SD), and 16 (40%) had PD. Patients treated with 2 prior regimens received greater benefit than patients treated with 1: PR/SD, 78.9% versus 42.9% (P =.03); median PFS, 10.9 versus 2.8 months (P =.08); median OS, 22.9 versus 12.8 months (P =.02). CONCLUSIONS: A weekly topotecan and biweekly bevacizumab combination demonstrates acceptable toxicity and encouraging efficacy in patients with platinum-resistant OC; further study is warranted.

Original languageEnglish (US)
Pages (from-to)3731-3740
Number of pages10
JournalCancer
Volume117
Issue number16
DOIs
StatePublished - Aug 15 2011

Keywords

  • angiogenesis inhibitors
  • fallopian tube cancer
  • ovarian cancer
  • primary peritoneal carcinoma
  • topotecan, chemotherapy

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'Combined weekly topotecan and biweekly bevacizumab in women with platinum-resistant ovarian, peritoneal, or fallopian tube cancer: Results of a Phase 2 Study'. Together they form a unique fingerprint.

  • Cite this

    McGonigle, K. F., Muntz, H. G., Vuky, J., Paley, P. J., Veljovich, D. S., Greer, B. E., Goff, B. A., Gray, H. J., & Malpass, T. W. (2011). Combined weekly topotecan and biweekly bevacizumab in women with platinum-resistant ovarian, peritoneal, or fallopian tube cancer: Results of a Phase 2 Study. Cancer, 117(16), 3731-3740. https://doi.org/10.1002/cncr.25967